Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04241146 · ClinicalTrials.gov registry record · NA

Optimal Feeding Tube Placement

A NA study of Enteral Feeding Intolerance, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT04241146: Completed NA study of Enteral Feeding Intolerance, sponsored by The University of Texas Health Science Center at San Antonio.

NCT04241146 is a NA study of Enteral Feeding Intolerance that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 52 participants, below the 76-participant average among 3 other Enteral Feeding Intolerance trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04241146, a NA study of Enteral Feeding Intolerance, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

A randomized controlled trial comparing current standard blind method to CORTRAK enteral access system (CEAS), an FDA approved electromagnetic device to place enteric tubes.

Primary Outcome

Time taken for placement of enteral tube

Interventions

  • DEVICE Enteric Tube
  • DEVICE CORTRAK enteral access system

Study Locations (1)

Texas

  • University Hospital - San Antonio

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2018-01-06
Est. Completion 2019-11-21
Phase NA

What the finished NCT04241146 record still lists

NCT04241146 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 76-participant average among 3 other Enteral Feeding Intolerance trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Enteral Feeding Intolerance appearing as the primary indexed condition, and to 2 interventions - of which Enteric Tube is the first listed.

NCT04241146 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04241146 about?

NCT04241146 is a clinical study titled "Optimal Feeding Tube Placement". A randomized controlled trial comparing current standard blind method to CORTRAK enteral access system (CEAS), an FDA approved electromagnetic device to place enteric tubes.

What is the current status of trial NCT04241146?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2018-01-06. Estimated completion is 2019-11-21.

What conditions does trial NCT04241146 study?

This clinical trial studies the following conditions: Enteral Feeding Intolerance.

What interventions are being tested in trial NCT04241146?

The interventions under investigation include: Enteric Tube (DEVICE), CORTRAK enteral access system (DEVICE).

Who is sponsoring clinical trial NCT04241146?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04241146 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Enteral Feeding Intolerance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04241146, the US trial registry maintained by the National Library of Medicine. NCT04241146 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.